Ageless Pep Academy Clinical Education · Licensed Prescribers

PMID-39222329 – Teriparatide in Postmenopausal Osteoporosis Meta-Analysis

PMID-39222329 – Teriparatide in Postmenopausal Osteoporosis Meta-Analysis

Abo-Zaid MA, El-Ashmawy NE, Barakat BM, et al. Teriparatide in postmenopausal osteoporosis: uncovering novel insights into efficacy and safety compared to other treatments – a systematic review and meta-analysis. BMC Musculoskelet Disord. 2024;25(1):725.

Quick Reference

Property Value
PMID 39222329
DOI 10.1186/s12891-024-07826-w
Year 2024
Journal BMC Musculoskeletal Disorders
Study Type Systematic Review / Meta-analysis
Evidence Level I
Sample 23 RCTs pooled
Peptide(s) Studied Teriparatide

Key Findings

  • Pooled analysis of 23 RCTs confirmed teriparatide significantly increases lumbar spine BMD and femoral neck BMD vs comparators
  • Fracture incidence was significantly reduced with teriparatide treatment despite an uptick in overall adverse events
  • Teriparatide showed superior BMD gains at lumbar spine compared to bisphosphonates and denosumab in head-to-head trials
  • Safety profile was acceptable; most adverse events were mild (nausea, dizziness, leg cramps, hypercalcemia)
  • Confirms the clinical utility of teriparatide specifically for high-risk postmenopausal osteoporosis patients who have failed or are intolerant of antiresorptive therapy

Study Design

Systematic review and meta-analysis following PRISMA 2020 guidelines. Searched PubMed, Cochrane, Scopus, and Web of Science for RCTs comparing teriparatide to other osteoporosis treatments or placebo in postmenopausal women. 23 RCTs met inclusion criteria. Outcomes included BMD changes at lumbar spine and femoral neck, fracture incidence, and adverse events. Risk of bias assessed using Cochrane RoB 2 tool.

Limitations

  • Heterogeneity across included studies in terms of treatment duration, comparator drugs, and population characteristics
  • Most studies were industry-funded
  • Publication bias cannot be entirely excluded
  • Limited data on long-term outcomes beyond 24 months in most included trials
  • Did not separate vertebral from non-vertebral fracture outcomes in the pooled analysis

Clinical Relevance

This comprehensive 2024 meta-analysis provides the most up-to-date synthesis of teriparatide efficacy data, confirming its position as the gold standard anabolic therapy for severe postmenopausal osteoporosis. The demonstrated superiority over bisphosphonates in BMD gains supports current guidelines recommending teriparatide for patients at very high fracture risk. The trade-off of slightly higher adverse event rates is offset by the clinically meaningful fracture reduction, particularly when sequential therapy (anabolic first, then antiresorptive) is employed.

Related

#research #systematic-review #meta-analysis #teriparatide #evidence-level-I